The growing economy has greatly changed the life style and diet of Chinese people and led to the increasing incidence of hypertension in China. According to population size and structure, China has over 300 million hypertensive patients, over 1/3 of the global total. However, China has a wide gap with developed countries on hypertension control rate. The new edition of List of Medicines Covered by National Basic Medical Insurance contains 271 cardiovascular drugs including 144 Chinese and western drugs and 127 Chinese patent drugs. It's worth mentioning that there are 6 cardiovascular drugs among the 36 drugs included in the list in 2017 after the second government-enterprise negotiation.
According to the researcher, the sales value of Valsartan was about CNY 537 million in 2017, a slight decrease over 2016. The sales volume increased while the average price fell, which doesn’t mean shrinking market demand.
There are many Valsartan manufacturers in China while the concentration ratio is high. In 2017, over 90% market share by sales value was captured by Beijing Novartis Pharma Co., Ltd., Lunan Better Pharmaceutical Co., Ltd., Novartis and Changzhou Siyao Pharmaceutical Co., Ltd. The Valsartan (trade name: Diovan) produced by Beijing Novartis Pharma Co., Ltd. took up over 85% of the Chinese market, and the domestic enterprises also gained some market share by price advantage. Many domestic pharmaceutical enterprises expect to scrabble for market shares from Novartis by advantage of lower prices. For example, in June 2018, Zhejiang Huahai Pharmaceutical Co., Ltd. obtained the production permit for Valsartan tablets (40mg, 80mg and160mg) from CFDA.
It is estimated that the incidence of hypertension and the demand for Valsartan will continue to grow in China in the coming years.
- Development environment of Valsartan in China
- Sales of Valsartan in China, 2013-2017
- Market share of major Valsartan manufacturers in China
- Sales of Valsartan in different dosage forms in China
- Average price of Valsartan in China
- Average prices of major manufacturers' Valsartan in China
- Prospects of Chinese Valsartan market
Table of Contents
1.2 Development History of Valsartan in China
1.3 Production Permit of Valsartan in China
2.1.1 Overall Sales Value
2.1.2 Sales Value in Different Regions
2.2 Sales Volume of Valsartan
2.2.1 Overall Sales Volume
2.2.2 Sales Volume in Different Regions
2.3 Sales of Valsartan in Different Dosage Forms in China
3.1.1 Market Shares by Sales Value
3.1.2 Market Shares by Sales Volume
3.2 Beijing Novartis Pharma Co., Ltd.
3.2.1 Profile of Beijing Novartis
3.2.2 Sales of Beijing Novartis' Valsartan
3.3 Lunan Better Pharmaceutical Co., Ltd.
3.5 Changzhou Siyao Pharmaceuticals Co., Ltd.
3.6 Hainan Hualon Pharmaceutical Co., Ltd.
3.7 China Resources Saike Pharmaceutical Co., Ltd.
4.1.1 Average Price
4.1.2 Prices of Valsartan in Different Dosage Forms
4.2 Prices of Valsartan of Different Enterprises
4.2.1 Beijing Novartis Pharma Co., Ltd.
4.2.2 Lunan Better Pharmaceutical Co., Ltd.
4.2.4 Changzhou Siyao Pharmaceuticals Co., Ltd.
4.2.5 Hainan Hualon Pharmaceutical Co., Ltd.
4.2.6 China Resources Saike Pharmaceutical Co., Ltd.
5.2 Forecast on Competition Pattern
Chart Sales Value of Valsartan in China, 2007-2017
Chart Sales Value of Valsartan Capsules in China, 2013-2017
Chart Sales Value of Valsartan Tablets in China, 2013-2017
Chart Market Shares of Valsartan Enterprises by Sales Value in China, 2013-2017
Chart Profile of Beijing Novartis Pharma Co., Ltd.
Chart Sales of Beijing Novartis's Valsartan, 2013-2017
Chart Prices of Beijing Novartis's Valsartan in Different Regions of China, 2017-2018
Chart Sales Value of Valsartan in China, 2013-2017
Chart Forecast on Size of Chinese Valsartan Market, 2018-2022
- Beijing Novartis Pharma Co., Ltd.
- Changzhou Siyao Pharmaceuticals Co., Ltd.
- China Resources Saike Pharmaceutical Co., Ltd.
- Hainan Hualon Pharmaceutical Co., Ltd.
- Lunan Better Pharmaceutical Co., Ltd.
Background research defines the range of products and industries, which proposes the key points of the research. Proper classification will help clients understand the industry and products in the report.
Secondhand material research is a necessary way to push the project into fast progress. The analyst always chooses the data source carefully. Most secondhand data they quote is sourced from an authority in a specific industry or public data source from governments, industrial associations, etc. For some new or niche fields, they also "double-check" data sources and logics before they show them to clients.
Primary research is the key to solve questions, which largely influence the research outputs. The analyst may use methods like mathematics, logical reasoning, scenario thinking, to confirm key data and make the data credible.
The data model is an important analysis method. Calculating through data models with different factors weights can guarantee the outputs objective.
The analyst optimizes the following methods and steps in executing research projects and also forms many special information gathering and processing methods.
1. Analyze the life cycle of the industry to understand the development phase and space.
2. Grasp the key indexes evaluating the market to position clients in the market and formulate development plans
3. Economic, political, social and cultural factors
4. Competitors like a mirror that reflects the overall market and also market differences.
5. Inside and outside the industry, upstream and downstream of the industry chain, show inner competitions
6. Proper estimation of the future is good guidance for strategic planning.